Shares of Sangamo Therapeutics Inc. (SGMO) were down nearly 11% to $7.30 on Wednesday, June 21. The Richmond, Calif.-based firm said it has priced an underwritten public offering of 10 million shares at $7.25 apiece, which would generate gross proceeds of $72.5 million before deducting the underwriting discounts and commissions and other offering expenses. The company has given the underwriters a 30-day option to buy up to an additional 1.5 million shares.

Sangamo said it plans to use the proceeds for working capital and other general corporate purposes. The company expects the offering to close on or about June 26.

Meanwhile, shares of Epizyme Inc. (EPZM) rose 4% to $14.30. The Cambridge, Mass.-based firm said the U.S. Food and Drug Administration has given orphan drug designation to tazemetostat, a EZH2 inhibitor for the treatment of patients with soft tissue sarcoma.

Among the other biotech movers include Revance Therapeutics Inc. (RVNC) . Shares of the Newark, Calif.-based firm were up 9.3% to $27.05.

More from Health

Is CBD Oil Legal? State-By-State and Future Legality

Is CBD Oil Legal? State-By-State and Future Legality

Unilever Taps In-House Executive as CEO

Unilever Taps In-House Executive as CEO

Open Enrollment Means Costly Changes for Some Medicare Advantage Beneficiaries

Open Enrollment Means Costly Changes for Some Medicare Advantage Beneficiaries

How Much Do Doctors Make in 2018?

How Much Do Doctors Make in 2018?

Coconut Oil: Benefits, Uses and Side Effects

Coconut Oil: Benefits, Uses and Side Effects